ArticleThe Lancet regional health. Europe2025

Efficacy and safety of SQ house dust mite sublingual immunotherapy-tablet (12 SQ-HDM) in children with allergic rhinitis/rhinoconjunctivitis with or without asthma (MT-12): a randomised, double-blind, placebo-controlled, phase III trial.

Antje Schuster et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.